Home | Konkai Consulting

KonKai Consulting

Scientific depth. Commercial results. Strategic consulting across

therapeutics, diagnostics, AI and translational platforms.

Our Capabilities

20+ years in science, BD and tech transfer

PhD in Immunology, Yale · Former Director of BD, Harvard OTD · Former VP Global Lead, Biomarkers, Cerba Research · Former Director of Translational Science, Enzo Life Sciences · Inventor on multiple patents

I work with therapeutics, diagnostics, AI and data-driven health platforms, CROs and lab-services companies, as well as universities and investors, turning complex science into partnerships, licenses, revenue and exit-ready enterprise value.

Unlock High-Impact Growth, Market Share and Enterprise Value

At KonKai, I work selectively with life sciences companies and CROs to transform complex science into commercially successful and strategically positioned platforms. I focus on laboratory service, diagnostics, translational research, and therapeutics, helping leadership teams create high-impact partnerships, licensing opportunities, and exit-ready strategies.

BOOK A 30 MINUTE FREE CONSULTATION

1

Strategic Partnerships

I help life sciences companies identify, evaluate, and structure high-impact partnerships that drive both scientific and commercial success. This involves assessing potential collaborators for strategic fit and market opportunity, designing deal structures that balance risk and value, and aligning partnerships with corporate goals to accelerate adoption, strengthen competitive positioning, and improve margins. My approach transforms partnerships from transactional arrangements into strategic levers that expand markets, unlock licensing opportunities, and maximize overall organizational impact.

2

Licensing Strategy

I work with life sciences companies to evaluate intellectual property and translational science to uncover high-value licensing opportunities that accelerate revenue and enterprise growth. This includes analyzing IP assets, market potential, and partner fit, and aligning agreements with strategic and commercial objectives. My approach turns complex intellectual property into strategic levers, creating measurable business impact and optionality for future partnerships, commercialization, or potential acquisition.

3

Commercialization

I work with leadership teams to align scientific innovation with commercial strategy, ensuring products and platforms reach their full market potential. This includes identifying adoption barriers, optimizing pricing and positioning, and integrating strategic partnerships to accelerate growth. My approach ensures that commercialization is a strategic driver, turning innovative technology into scalable, profitable, and sustainable offerings that create measurable impact across the organization.

Eitan Akirav, Ph.D.

Founder & CEO

My Story

I founded KonKai Consulting, part of KonKai Ventures, LLC, in 2022 after two decades bridging the lab and the deal table: a Yale PhD in immunology, translational science at Enzo Life Sciences, global biomarker leadership at Cerba Research, and business development at Harvard's Office of Technology Development.

Today I work selectively with therapeutics, diagnostics, AI-driven health and research-services companies, and with the universities and investors behind them. This includes embedded commercial leadership at Bio X Cell, a Windjammer Capital portfolio company. My network of C-suite leaders across biotech, pharma, CROs, venture capital and investment banking helps clients move faster on partnerships, alliances and revenue.

Clients count on me for integrity, focus and on-time delivery.